HitGen Inc. entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co. Ltd. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.52 CNY | +1.27% | +16.45% | -9.81% |
Apr. 24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.81% | 746M | |
-1.52% | 104B | |
+6.61% | 97.47B | |
+5.71% | 22.25B | |
-12.95% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-9.82% | 16.36B | |
+8.13% | 14.39B | |
+37.06% | 12.37B |
- Stock Market
- Equities
- 688222 Stock
- News HitGen Inc.
- DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery